Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

39.50 -0.82 (-2.03%)
Official Closing Price Updated: 7:00 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
37 38 Next >
AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants
The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ: AZN) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab).... 
Via Benzinga
Canada Approves First Plant-Based COVID-19 Vaccine
As Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc's (NYSE: GSK) COVID-19 vaccine finally heads to regulators, another shot using GSK's pandemic... 
Via Benzinga
Red Ink
There is little joy in stocks today as even companies reporting good results are being hit by fear of Ukraine sanctions.tbph 
Via Talk Markets
A Receding tide
Sanofi and GlaxoSmithKline have developed a new Covid-19 vaccine which they claim is 100% efficient. 
Via Talk Markets
Earnings Scheduled For February 9, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. 
Via Benzinga
A Look Into GlaxoSmithKline's Price Over Earnings
  
Via Benzinga
Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as... 
Via Benzinga
Holiday Over
China is busily avoiding taking sides between Ukraine and Russia. 
Via Talk Markets
Dividend Income Update January 2022
With February already underway it is time for all dividend income investors to look back at the previous month and see how much passive dividend income our portfolios generated. 
Via Talk Markets
"Prudent" Biotech Bets
Here, we review two recommended biotechnology stocks following the release of their latest earnings reports. Let's take a look. 
Via Talk Markets
70 Firms Going Ex-Dividend Next Week, Including GlaxoSmithKline, Dow And AstraZeneca
Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend. 
Via Talk Markets
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
UK High Yield Dividend Aristocrats 2022
The UK High Yield Dividend Aristocrats 2022 are UK stocks that have increased or maintained their dividend for at least ten consecutive years. However, that fact alone does not qualify a stock as an UK... 
Via Talk Markets
Moderna Adds Three New mRNA-Based Development Programs To Its Pipeline
Moderna Inc (NASDAQ: MRNA) said it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection... 
Via Benzinga
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
GlaxoSmithKline plc (NYSE: GSK) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety... 
Via Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO... 
Via Benzinga
Give peace a chance
Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today. 
Via Talk Markets
The Best Russell 2000 Stocks to Buy Before they Rebound
Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices. 
Via InvestorPlace
World Markets News For Monday
European markets were down over fear of Ukrainian battles. 
Via Talk Markets
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
Stock Market Rally Stalls As Inflation, Treasury Yields Soar: Weekly Review
The stock market rally remains stuck in a recent range as the major indexes slashed weekly gains on hot inflation. Treasury yields surged. 
Via Investor's Business Daily
Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant
In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc (NYSE 
Via Benzinga
Why Are Seagen Shares Sinking Today?
Seagen Inc (NASDAQ: SGEN) reported Q4 revenues 
Via Benzinga
Dampening Exuberance
The bond sell-off halted today but the Fed's plans mean this will resume. 
Via Talk Markets
GlaxoSmithKline: Q4 Earnings Insights
  GlaxoSmithKline (NYSE:GSK) reported its Q4 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Glaxo's Q4 Pharma Sales Jump 20% Boosted By COVID-19 Treatment; Prepares For Spin-Off
GlaxoSmithKline Plc's (NYSE: GSK) turnover was  
Via Benzinga
Immunome Shares Seesaw After COVID-19 Antibody Cocktail Works Against Live Omicron Virus
Immunome Inc (NASDAQ: IMNM) shares rose before falling after reporting results from testing its experimental three-antibody cocktail  
Via Benzinga
Key Events This Week: All Eyes On The CPI
After what DB's Jim Reid describes as 
Via Talk Markets
A News Blizzard
Markets are still down despite very encouraging news in January when 467,00 new hires got jobs. 
Via Talk Markets
Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars
Sanofi SA's (NASDAQ: SNY)  
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.